<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2023-22-6-92-102</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-2839</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LABORATORY AND EXPERIMENTAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Сопряженность цитокинового профиля супернатанта инвазивной карциномы молочной железы с ее молекулярными и гистопатологическими характеристиками</article-title><trans-title-group xml:lang="en"><trans-title>Relationship between the cytokine profile of supernatants of invasive breast carcinoma and its molecular and histopathological characteristics</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7180-010X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аутеншлюс</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Autenshlyus</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аутеншлюс Александр Исаевич - доктор биологических наук, профессор, заведующий Центральной научно-исследовательской лабораторией, 630091, г. Новосибирск, Красный проспект, 52;</p><p>главный научный сотрудник, 630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Alexander I. Autenshlyus - Professor, Head of Central Research Laboratory, 52, Krasny Ave., Novosibirsk, 630091;</p><p>Chief Researcher, 2, Timakova St., Novosibirsk, 630117</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1390-4426</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Архипов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Arkhipov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Архипов Сергей Алексеевич - доктор биологических наук, ведущий научный сотрудник, Центральная научно-исследовательская лаборатория, 630091, г. Новосибирск, Красный проспект, 52;</p><p>старший научный сотрудник, 630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Sergey A. Arkhipov - DSc, Leading Researcher, Central Research Laboratory, 52, Krasny Ave., Novosibirsk, 630091;</p><p>Senior Researcher, 2, Timakova St., Novosibirsk, 630117</p></bio><email xlink:type="simple">arhipowsergei@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8364-819X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Михайлова</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Mikhaylova</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михайлова Елена Семеновна - научный сотрудник, Центральная научно-исследовательская лаборатория, 630091, г. Новосибирск, Красный проспект, 52;</p><p>научный сотрудник, 630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Elena S. Mikhailova - Researcher, Central Research Laboratory, 52, Krasny Ave., Novosibirsk, 630091;</p><p>Researcher, 2, Timakova St., Novosibirsk, 630117</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-0172-0905</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Архипова</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Arkhipova</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Архипова Валентина Валериевна - младший научный сотрудник, Центральная  научно-исследовательская лаборатория, </p><p>630091, г. Новосибирск, Красный проспект, 52</p></bio><bio xml:lang="en"><p>Valentina V. Arkhipova - Junior Researcher, Central Research Laboratory,</p><p>52, Krasny Ave., Novosibirsk, 630091</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0733-7787</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вараксин</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Varaksin</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вараксин Николай Анатольевич - заведующий лабораторией цитокинов, </p><p>630559, Новосибирская обл., пос. Кольцово</p></bio><bio xml:lang="en"><p>Nikolay A. Varaksin - Head of Cytokine Laboratory, </p><p>Koltsovo, Novosibirsk Region, 630559</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России;&#13;
Научно-исследовательский институт молекулярной биологии и биофизики, ФГБНУ ФИЦ фундаментальной и трансляционной медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University;&#13;
Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России;&#13;
Научно-исследовательский институт молекулярной биологии и биофизики,&#13;
ФГБНУ ФИЦ фундаментальной и трансляционной медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University;&#13;
Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>АО «Вектор-Бест»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vector-Best</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>03</day><month>01</month><year>2024</year></pub-date><volume>22</volume><issue>6</issue><fpage>92</fpage><lpage>102</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Аутеншлюс А.И., Архипов С.А., Михайлова Е.С., Архипова В.В., Вараксин Н.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Аутеншлюс А.И., Архипов С.А., Михайлова Е.С., Архипова В.В., Вараксин Н.А.</copyright-holder><copyright-holder xml:lang="en">Autenshlyus A.I., Arkhipov S.A., Mikhaylova E.S., Arkhipova V.V., Varaksin N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/2839">https://www.siboncoj.ru/jour/article/view/2839</self-uri><abstract><p>Цель исследования – изучение сопряженности между показателями цитокинового профиля супернатантов образцов инвазивной карциномы молочной железы неспецифического типа (ИКНТ), ее молекулярными и гистопатологическими параметрами, экспрессией CD34 как маркера ангиогенеза и метастазированием в регионарные лимфатические узлы (РЛУ).</p><sec><title>Материал и методы</title><p>Материал и методы. В биоптатах ИКНТ от 28 пациенток в возрасте 37–60 лет исследовали продукцию 14 цитокинов. Концентрацию цитокинов в супернатантах биоптатов (КЦСБ) определяли (в пг/мл) с помощью иммуноферментного анализа (ИФА). Экспрессию CD34 и маркеров молекулярных подтипов ИКНТ (HER2/neu, ER, PR, Ki67) в биоптатах ИКНТ оценивали иммуногистохимическим методом. Относительное содержание опухолевых клеток различной степени дифференцировки в образцах ИКНТ оценивали гистопатологическим анализом.</p></sec><sec><title>Результаты</title><p>Результаты. Значимые различия между пациентами I группы (с метастазами в регионарных лимфатических узлах (РЛУ)) и II группы (без метастазов в РЛУ) выявлены при оценке КЦСБ: IFN-γ, G-CSF, IL-2, IL-10 и MCP-1. В I группе выявлены корреляционные связи между рядом гистопатологических параметров (экспрессии HER2/neu, CD34 и Ki67, % митозов и низкодифференцированных опухолевых клеток) и КЦСБ (MCP-1, IL-18). Во II группе также выявлены корреляционные связи между КЦСБ (IL-2, VEGF-A, G-CSF, IL-1Ra) и некоторыми гистопатологическими параметрами ИКНТ (экспрессии HER2/neu, CD34, PR, % митозов и высокодифференцированных опухолевых клеток). С помощью ROC-анализа установлено, что на основе показателей экспрессии CD34 и КЦСБ IL-10, G-CSF, MCP-1 в образцах ИКНТ можно прогнозировать наличие или отсутствие метастазов в РЛУ. Качество модели для разделения больных на группу без метастазов в РЛУ и на группу с метастазами, основанного на оценке КЦСБ MCP-1, достигало максимальных значений (AUC=1,000) при относительно высоких показателях экспрессии CD34.</p></sec><sec><title>Заключение</title><p>Заключение. Анализ полученных данных показал важность оценки экспрессии CD34 и продукции ряда цитокинов клетками биоптатов ИКНТ для прогнозирования наличия или отсутствия метастазов в РЛУ.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to analyze the correlation between the cytokine profile of supernatants of invasive breast carcinoma of a nonspecific type (IBC-NST) samples, histopathological and molecular genetic parameters of IBC-NST, expression of the CD34 as a marker of angiogenesis and metastasis to regional lymph nodes (RLN).</p><sec><title>Material and Methods</title><p>Material and Methods. The production of 14 cytokines in IBC-NST biopsy samples from 28 patients aged 37–60 years was studied. The concentration of cytokines in the supernatants of biopsies (CCSB) was determined (in pg/ml) using enzyme immunoassay (ELISA). The expression of CD34 and markers of IBC-NST molecular subtypes (HER2/neu, ER, PR, Ki67) in IBC-NST biopsy samples was evaluated by immunohistochemical method. The relative content of tumor cells of different differentiation grade in the IBC- NST samples was evaluated by histopathological analysis.</p></sec><sec><title>Results</title><p>Results. The assessment of CCSB showed statistically significant differences in IFN-γ, G-CSF, IL-2, IL-10 and MCP-1 between patients of group I (with metastases in RLNs) and group II (without metastases in RLNs). In group I, the correlations between histopathological parameters (Her2/neu, CD34 and Ki67 expressions, % of mitoses and poorly-differentiated cancer cells) and CCSB (MCP-1, IL-18) were revealed. In group II, the correlations between CCSB (IL-2, VEGF-A, G-CSF, IL-1Ra) and histopathological parameters, such as expression of Her2/neu, CD34, PR, % of mitoses and well-differentiated cancer cells, were revealed. The ROC analysis showed that the presence or absence of metastases in RLNs can be predicted on the basis of CD34 expression levels and concentrations of IL-10, G-CSF, and MCP-1 in supernatants of IBC-NST biopsy samples. The quality of the model for stratifying patients into groups with and without RLN metastases, based on the assessment of the concentration of MCP-1 in the supernatants of IBC-NST biopsies, reached maximum values (AUC=1.000) with relatively high CD34 expression.</p></sec><sec><title>Conclusion</title><p>Conclusion. The analysis of the data obtained showed that the assessment of CD34 expression and production of cytokines in IBC-NST biopsies is important for predicting the presence or absence of metastases in RLNs.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>инвазивная карцинома молочной железы неспецифического типа</kwd><kwd>гистопатологические параметры</kwd><kwd>маркеры молекулярных подтипов</kwd><kwd>CD34</kwd><kwd>цитокины</kwd><kwd>метастазы в региональные лимфатические узлы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>invasive breast carcinoma of non-specific type</kwd><kwd>histopathological parameters</kwd><kwd>markers of molecular subtypes</kwd><kwd>CD34</kwd><kwd>cytokines</kwd><kwd>metastases to regional lymph nodes</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование профинансировано в рамках государственного задания (№ АААА-А18-118030790008-7) Министерства здравоохранения Российской Федерации.</funding-statement><funding-statement xml:lang="en">The study was funded within the framework of the state task (no. AAAAA-A18-118030790008-7) of the Ministry of Health of the Russian Federation.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Korkaya H., Orsulic S. Editorial: The tumor microenvironment: Recent advances and novel therapeutic approaches. Front Cell Dev Biol. 2020; 8. doi: 10.3389/fcell.2020.586176.</mixed-citation><mixed-citation xml:lang="en">Korkaya H., Orsulic S. Editorial: The tumor microenvironment: Recent advances and novel therapeutic approaches. Front Cell Dev Biol. 2020; 8. doi: 10.3389/fcell.2020.586176.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Esquivel-Velazquez M.E., Ostoa-Saloma P., Palacios-Arreola M.I., Nava-Castro K.E., Castro J.I., Montor J.M. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015; 35(1): 1–16. doi: 10.1089/jir.2014.0026.</mixed-citation><mixed-citation xml:lang="en">Esquivel-Velazquez M.E., Ostoa-Saloma P., Palacios-Arreola M.I., Nava-Castro K.E., Castro J.I., Montor J.M. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015; 35(1): 1–16. doi: 10.1089/jir.2014.0026.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Panis C., Pavanelli W.R. Cytokines as mediators of painrelated process in breast cancer. Mediators Inflamm. 2015. doi: 10.1155/2015/129034.</mixed-citation><mixed-citation xml:lang="en">Panis C., Pavanelli W.R. Cytokines as mediators of painrelated process in breast cancer. Mediators Inflamm. 2015. doi: 10.1155/2015/129034.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Paccagnella M., Abbona A., Michelotti A., Geuna E., Ruatta F., Landucci E., Denaro N., Vanella P., Lo Nigro C., Galizia D., Merlano M., Garrone O. Circulating cytokines in metastatic breast cancer patients select diferent prognostic groups and patients who might beneft from treatment beyond progression. Vaccines (Basel). 2022; 10(1): 78. doi: 10.3390/vaccines10010078.</mixed-citation><mixed-citation xml:lang="en">Paccagnella M., Abbona A., Michelotti A., Geuna E., Ruatta F., Landucci E., Denaro N., Vanella P., Lo Nigro C., Galizia D., Merlano M., Garrone O. Circulating cytokines in metastatic breast cancer patients select diferent prognostic groups and patients who might beneft from treatment beyond progression. Vaccines (Basel). 2022; 10(1): 78. doi: 10.3390/vaccines10010078.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yu-Ling L., Hua Z., Xiu-Bao R. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med. 2016; 13(2): 206–14. doi: 10.20892/j.issn.2095-3941.2015.0070.</mixed-citation><mixed-citation xml:lang="en">Yu-Ling L., Hua Z., Xiu-Bao R. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med. 2016; 13(2): 206–14. doi: 10.20892/j.issn.2095-3941.2015.0070.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sun Y., Ai X., Shen S., Gu L., Lu S. Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases. Patient Prefer Adherence. 2015; 9: 1165–9. doi: 10.2147/PPA.S86605.</mixed-citation><mixed-citation xml:lang="en">Sun Y., Ai X., Shen S., Gu L., Lu S. Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases. Patient Prefer Adherence. 2015; 9: 1165–9. doi: 10.2147/PPA.S86605.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chen W., Qin T., Liu S. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clin Trans Med. 2018; 7(1): 27. doi: 10.1186/s40169-018-0205-6.</mixed-citation><mixed-citation xml:lang="en">Chen W., Qin T., Liu S. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clin Trans Med. 2018; 7(1): 27. doi: 10.1186/s40169-018-0205-6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jabeen S., Espinoza J.A., Torland L.A., Zucknick M., Kumar S., Haakensen V.D., Lüders T., Engebraaten O., Børresen-Dale A., Kyte J.A., Gromov P., Naume B., Kristensen V., Gromova I., Tekpli X. Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics. OncoImmunology. 2018; 8(2). doi: 10.1080/2162402X.2018.1537691.</mixed-citation><mixed-citation xml:lang="en">Jabeen S., Espinoza J.A., Torland L.A., Zucknick M., Kumar S., Haakensen V.D., Lüders T., Engebraaten O., Børresen-Dale A., Kyte J.A., Gromov P., Naume B., Kristensen V., Gromova I., Tekpli X. Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics. OncoImmunology. 2018; 8(2). doi: 10.1080/2162402X.2018.1537691.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kawaguchi K., Sakurai M., Yamamoto Y., Suzuki E., Tsuda M., Kataoka T.R., Hirata M., Nishie M., Nojiri T., Kumazoe M., Saito K., Toi M. Alteration of specifc cytokine expression patterns in patients with breast cancer. Sci Rep. 2019; 9(1): 2924. doi: 10.1038/s41598-019-39476-9.</mixed-citation><mixed-citation xml:lang="en">Kawaguchi K., Sakurai M., Yamamoto Y., Suzuki E., Tsuda M., Kataoka T.R., Hirata M., Nishie M., Nojiri T., Kumazoe M., Saito K., Toi M. Alteration of specifc cytokine expression patterns in patients with breast cancer. Sci Rep. 2019; 9(1): 2924. doi: 10.1038/s41598-019-39476-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Engel J., Eckel R., Halfter K., Schubert-Fritschle G., Hölzel D. Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data. J Cancer Res and Clin Oncol. 2023; 149(2): 721–35. doi:10.1007/s00432-022-04369-4.</mixed-citation><mixed-citation xml:lang="en">Engel J., Eckel R., Halfter K., Schubert-Fritschle G., Hölzel D. Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data. J Cancer Res and Clin Oncol. 2023; 149(2): 721–35. doi:10.1007/s00432-022-04369-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gong G., Kwon M. J., Han J., Lee H.J., Lee S.K., Lee J.E., Lee S.H., Park S., Choi J.S., Cho S.Y., Ahn S.H., Lee J.W., Cho S.R., Moon Y., Nam B.H., Nam S.J., Choi Y.L., Shin Y.K. A new molecular prognostic score for predicting the risk of istant metastasis in patients with HR+/HER2- early breast cancer. Scientifc Reports. 2017; 7. doi:10.1038/srep45554.</mixed-citation><mixed-citation xml:lang="en">Gong G., Kwon M. J., Han J., Lee H.J., Lee S.K., Lee J.E., Lee S.H., Park S., Choi J.S., Cho S.Y., Ahn S.H., Lee J.W., Cho S.R., Moon Y., Nam B.H., Nam S.J., Choi Y.L., Shin Y.K. A new molecular prognostic score for predicting the risk of istant metastasis in patients with HR+/HER2- early breast cancer. Scientifc Reports. 2017; 7. doi:10.1038/srep45554.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang K., Luo Z., Zhang Y., Song X., Zhang L., Wu L., Liu J. Long non-coding RNAs as novel biomarkers for breast cancer invasion and metastasis. Oncology Lett. 2017; 14(2): 1895–904. doi: 10.3892/ol.2017.6462.</mixed-citation><mixed-citation xml:lang="en">Zhang K., Luo Z., Zhang Y., Song X., Zhang L., Wu L., Liu J. Long non-coding RNAs as novel biomarkers for breast cancer invasion and metastasis. Oncology Lett. 2017; 14(2): 1895–904. doi: 10.3892/ol.2017.6462.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lee K.K., Chng W.J., Jha S. Prognostic biomarkers for breast cancer metastasis. Cancer Metastasis. 2018: 96–113. doi: 10.5772/intechopen.80576.</mixed-citation><mixed-citation xml:lang="en">Lee K.K., Chng W.J., Jha S. Prognostic biomarkers for breast cancer metastasis. Cancer Metastasis. 2018: 96–113. doi: 10.5772/intechopen.80576.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wu X., Baig A., Kasymjanova G., Kaf K., Holcroft C., Mekouar H., Carbonneau A., Bahoric B., Sultanem K., Muanza T. Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus. 2016; 8(12). doi: 10.7759/cureus.924.</mixed-citation><mixed-citation xml:lang="en">Wu X., Baig A., Kasymjanova G., Kaf K., Holcroft C., Mekouar H., Carbonneau A., Bahoric B., Sultanem K., Muanza T. Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus. 2016; 8(12). doi: 10.7759/cureus.924.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed A.A., Hassen A., Osman N., Elroufaie H. Immunohistochemical expression of angiogenic marker CD34 in invasive carcinoma of the breast. Eur Acad Res. 2015; 3(9): 9592–600.</mixed-citation><mixed-citation xml:lang="en">Ahmed A.A., Hassen A., Osman N., Elroufaie H. Immunohistochemical expression of angiogenic marker CD34 in invasive carcinoma of the breast. Eur Acad Res. 2015; 3(9): 9592–600.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z., Xu S., Xu W., Huang J., Zhang G.U., Lei L., Shao X., Wang X. Expression of cluster of diferentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic signifcance. Oncol Lett. 2015; 10(2): 723–9. doi: 10.3892/ol.2015.3348.</mixed-citation><mixed-citation xml:lang="en">Chen Z., Xu S., Xu W., Huang J., Zhang G.U., Lei L., Shao X., Wang X. Expression of cluster of diferentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic signifcance. Oncol Lett. 2015; 10(2): 723–9. doi: 10.3892/ol.2015.3348.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Khan A.A., Alam K., Harris H. A Clinicopathological study of CD34 antigen expression in benign and malignant breast lesions. J Clin Exp Pathol. 2017; 7(4): 321. doi:10.4172/2161-0681.1000321.</mixed-citation><mixed-citation xml:lang="en">Khan A.A., Alam K., Harris H. A Clinicopathological study of CD34 antigen expression in benign and malignant breast lesions. J Clin Exp Pathol. 2017; 7(4): 321. doi:10.4172/2161-0681.1000321.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mehdi Hassanpour M., Salybekov A., Kobayashi S., Asahara T. CD34 positive cells as endothelial progenitor cells in biology and medicine. Front Cell Dev Biol. 2023; 17: 11: 1128134. doi: 10.3389/fcell.2023.1128134.</mixed-citation><mixed-citation xml:lang="en">Mehdi Hassanpour M., Salybekov A., Kobayashi S., Asahara T. CD34 positive cells as endothelial progenitor cells in biology and medicine. Front Cell Dev Biol. 2023; 17: 11: 1128134. doi: 10.3389/fcell.2023.1128134.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chen M., Sun H., Zhao Y., Fu W., Yang L., Gao S., Li L., Jiang H., Jin W. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: A SEER population-based analysis. Sci Rep. 2017; 7(1). doi: 10.1038/s41598-017-10166-8.</mixed-citation><mixed-citation xml:lang="en">Chen M., Sun H., Zhao Y., Fu W., Yang L., Gao S., Li L., Jiang H., Jin W. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: A SEER population-based analysis. Sci Rep. 2017; 7(1). doi: 10.1038/s41598-017-10166-8.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cai S., Zuo W., Lu X., Gou Z., Zhou Y., Liu P., Pan Y., Chen S. The prognostic impact of age at diagnosis upon breast cancer of diferent immunohistochemical subtypes: a surveillance, epidemiology, and end results (SEER) population-based analysis. Front Oncol. 2020; 10: 1729. doi: 10.3389/fonc.2020.01729.</mixed-citation><mixed-citation xml:lang="en">Cai S., Zuo W., Lu X., Gou Z., Zhou Y., Liu P., Pan Y., Chen S. The prognostic impact of age at diagnosis upon breast cancer of diferent immunohistochemical subtypes: a surveillance, epidemiology, and end results (SEER) population-based analysis. Front Oncol. 2020; 10: 1729. doi: 10.3389/fonc.2020.01729.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kondov B., Milenkovikj Z., Kondov G., Petrushevska G., Basheska N., Bogdanovska-Todorovska M., Tolevska N., Ivkovski L. Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients. J Med Sci. 2018; 6(6): 961–7. doi: 10.3889/oamjms.2018.231.</mixed-citation><mixed-citation xml:lang="en">Kondov B., Milenkovikj Z., Kondov G., Petrushevska G., Basheska N., Bogdanovska-Todorovska M., Tolevska N., Ivkovski L. Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients. J Med Sci. 2018; 6(6): 961–7. doi: 10.3889/oamjms.2018.231.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Autenshlyus A., Arkhipov S., Kunts T., Marinkin I., Mikhailova E., Karpukhina X., Varaksin N. Cytokine profles of tumor supernatants in invasive ductal cancer and fbroadenoma of the breast and its relationship with VEGF-A expression in the tumors. Int J Immunopathol Pharmacol. 2017; 30(1): 83–8. doi: 10.1177/0394632016681306.</mixed-citation><mixed-citation xml:lang="en">Autenshlyus A., Arkhipov S., Kunts T., Marinkin I., Mikhailova E., Karpukhina X., Varaksin N. Cytokine profles of tumor supernatants in invasive ductal cancer and fbroadenoma of the breast and its relationship with VEGF-A expression in the tumors. Int J Immunopathol Pharmacol. 2017; 30(1): 83–8. doi: 10.1177/0394632016681306.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Agilent [Internet]. ER/PR PharmDx Interpretation Manual. URL: https://www.agilent.com/cs/library/usermanuals/public/28252_erpr_pharmdx_interpretation_manual.pdf [cited 01.12.2023].</mixed-citation><mixed-citation xml:lang="en">Agilent [Internet]. ER/PR PharmDx Interpretation Manual. URL: https://www.agilent.com/cs/library/usermanuals/public/28252_erpr_pharmdx_interpretation_manual.pdf [cited 01.12.2023].</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">National Cancer Institute [Internet]. Tumor Grade/ How tumor grade is determined. URL: https://www.cancer.gov/about-cancer/diagnosisstaging/diagnosis/tumor-grade [cited 02.12.2023].</mixed-citation><mixed-citation xml:lang="en">National Cancer Institute [Internet]. Tumor Grade/ How tumor grade is determined. URL: https://www.cancer.gov/about-cancer/diagnosisstaging/diagnosis/tumor-grade [cited 02.12.2023].</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">National Cancer Institute [Internet]. Center for Cancer Genomics. The Cancer Genome Atlas Program (TCGA) https://www.cancer.gov/ccg/research/genome-sequencing/tcga [cited 02.12.2023].</mixed-citation><mixed-citation xml:lang="en">National Cancer Institute [Internet]. Center for Cancer Genomics. The Cancer Genome Atlas Program (TCGA) https://www.cancer.gov/ccg/research/genome-sequencing/tcga [cited 02.12.2023].</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Gui P., Bivona T.G. Evolution of metastasis: new tools and insights. Trends Cancer. 2022; 8(2): 98–109. doi: 10.1016/j.trecan.2021.11.002.</mixed-citation><mixed-citation xml:lang="en">Gui P., Bivona T.G. Evolution of metastasis: new tools and insights. Trends Cancer. 2022; 8(2): 98–109. doi: 10.1016/j.trecan.2021.11.002.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Reiter J., Makohon-Moore A., Gerold J., Heyde A., Attiyeh M., Kohutek Z., Tokheim C., Brown A., DeBlasio R., Niyazov J., Zucker A., Karchin R., Kinzler R., Iacobuzio-Donahue C., Vogelstein B., Nowak M. Minimal functional driver gene heterogeneity among untreated metastases. Science. 2018; 361(6406): 1033–7. doi: 10.1126/science.aat7171.</mixed-citation><mixed-citation xml:lang="en">Reiter J., Makohon-Moore A., Gerold J., Heyde A., Attiyeh M., Kohutek Z., Tokheim C., Brown A., DeBlasio R., Niyazov J., Zucker A., Karchin R., Kinzler R., Iacobuzio-Donahue C., Vogelstein B., Nowak M. Minimal functional driver gene heterogeneity among untreated metastases. Science. 2018; 361(6406): 1033–7. doi: 10.1126/science.aat7171.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bertucci F., Ng C., Patsouris A., Droin N., Piscuoglio S., Carbuccia N., Soria J., Dien A., Adnani Y., Kamal M., Garnier S., Meurice G., Jimenez M., Dogan S., Verret B., Chaffanet M., Bachelot T., Campone M., Lefeuvre C., Bonnefoi H., Dalenc F., Jacquet A., De FilippoM., Babbar N., Birnbaum D., Filleron T., Tourneau C., Andre F. Genomic characterization of metastatic breast cancers. Nature. 2019; 569(7757): 560–4. doi: 10.1038/s41586-019-1056-z.</mixed-citation><mixed-citation xml:lang="en">Bertucci F., Ng C., Patsouris A., Droin N., Piscuoglio S., Carbuccia N., Soria J., Dien A., Adnani Y., Kamal M., Garnier S., Meurice G., Jimenez M., Dogan S., Verret B., Chaffanet M., Bachelot T., Campone M., Lefeuvre C., Bonnefoi H., Dalenc F., Jacquet A., De FilippoM., Babbar N., Birnbaum D., Filleron T., Tourneau C., Andre F. Genomic characterization of metastatic breast cancers. Nature. 2019; 569(7757): 560–4. doi: 10.1038/s41586-019-1056-z.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Priestley P., Baber J., Lolkema M., Steeghs N., Bruijn E., Shale C., Duyvesteyn K., Haidari S., Hoeck A., Onstenk W., Roepman P., Voda M., Bloemendal H., Tjan-Heijnen V., Herpen C., Labots M., Witteveen P., Smit E., Sleijfer S., Voest E., Cuppen E. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019; 575(7781): 210–6. doi: 10.1038/s41586-019-1689-y.</mixed-citation><mixed-citation xml:lang="en">Priestley P., Baber J., Lolkema M., Steeghs N., Bruijn E., Shale C., Duyvesteyn K., Haidari S., Hoeck A., Onstenk W., Roepman P., Voda M., Bloemendal H., Tjan-Heijnen V., Herpen C., Labots M., Witteveen P., Smit E., Sleijfer S., Voest E., Cuppen E. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019; 575(7781): 210–6. doi: 10.1038/s41586-019-1689-y.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Markopoulos G., Roupakia E., Marcu K., Kolettas E. Epigenetic regulation of infammatory cytokine-induced epithelial-to-mesenchymal cell transition and cancer stem cell generation. Cells. 2019; 8(10). doi:10.3390/cells8101143.</mixed-citation><mixed-citation xml:lang="en">Markopoulos G., Roupakia E., Marcu K., Kolettas E. Epigenetic regulation of infammatory cytokine-induced epithelial-to-mesenchymal cell transition and cancer stem cell generation. Cells. 2019; 8(10). doi:10.3390/cells8101143.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Dai E., Zhu Z., Wahed S., Qu Z., Storkus W.J., Guo Z.S. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021; 20(1): 171. doi: 10.1186/s12943-021-01464-x.</mixed-citation><mixed-citation xml:lang="en">Dai E., Zhu Z., Wahed S., Qu Z., Storkus W.J., Guo Z.S. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021; 20(1): 171. doi: 10.1186/s12943-021-01464-x.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021; 101(Pt B). doi: 10.1016/j.intimp.2021.107598.</mixed-citation><mixed-citation xml:lang="en">Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021; 101(Pt B). doi: 10.1016/j.intimp.2021.107598.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">The Human Protein Atlas [Internet]. CCL2. Breast cancer. URL: https://www.proteinatlas.org/ENSG00000108691-CCL2/pathology/breast+cancer#imid_3293972 [cited 18.11.2023].</mixed-citation><mixed-citation xml:lang="en">The Human Protein Atlas [Internet]. CCL2. Breast cancer. URL: https://www.proteinatlas.org/ENSG00000108691-CCL2/pathology/breast+cancer#imid_3293972 [cited 18.11.2023].</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Dong Y., Zhang S., Zhao S., Xuan M., Zhu G., Zhang Z., Guo W. CCL2 promotes lymphatic metastasis via activating RhoA and Rac1 pathway and predict prognosis to some extent in tongue cancer. Cancer Biol Ther. 2023; 24(1). doi: 10.1080/15384047.2023.2205342.</mixed-citation><mixed-citation xml:lang="en">Dong Y., Zhang S., Zhao S., Xuan M., Zhu G., Zhang Z., Guo W. CCL2 promotes lymphatic metastasis via activating RhoA and Rac1 pathway and predict prognosis to some extent in tongue cancer. Cancer Biol Ther. 2023; 24(1). doi: 10.1080/15384047.2023.2205342.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">The Human Protein Atlas [Internet]. IL18. Breast cancer. URL: https://www.proteinatlas.org/ENSG00000150782-IL18/pathology/ breast+cancer#imid_2204142 [cited 18.11.2023].</mixed-citation><mixed-citation xml:lang="en">The Human Protein Atlas [Internet]. IL18. Breast cancer. URL: https://www.proteinatlas.org/ENSG00000150782-IL18/pathology/ breast+cancer#imid_2204142 [cited 18.11.2023].</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
